MANNKIND CORP Increase (Decrease) in Other Noncurrent Liabilities
MANNKIND CORP (MNKD) reported Increase (Decrease) in Other Noncurrent Liabilities of -$4.95 million for the 12-month period ending 2022-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities · last filed 2025-02-26
- MANNKIND CORP increase (decrease) in other noncurrent liabilities for the quarter ending 2022-12-31 was $0.00.
- MANNKIND CORP increase (decrease) in other noncurrent liabilities for the quarter ending 2022-09-30 was -$1.56M.
- MANNKIND CORP increase (decrease) in other noncurrent liabilities for the quarter ending 2022-06-30 was -$5.49M.
- MANNKIND CORP increase (decrease) in other noncurrent liabilities for the quarter ending 2022-03-31 was $2.10M.
- MANNKIND CORP increase (decrease) in other noncurrent liabilities for fiscal 2022 was -$4.95M, a 200.00% decline from fiscal 2021.
- MANNKIND CORP increase (decrease) in other noncurrent liabilities for fiscal 2021 was $4.95M.
| Period end | Increase (Decrease) in Other Noncurrent Liabilities 3 month | Increase (Decrease) in Other Noncurrent Liabilities 6 month | Increase (Decrease) in Other Noncurrent Liabilities 9 month | Increase (Decrease) in Other Noncurrent Liabilities 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$1.56M derived: sum of 2 quarters · filed 2025-02-26 | -$7.05M derived: sum of 3 quarters · filed 2025-02-26 | -$4.95M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$7.05M derived: sum of 2 quarters · filed 2023-11-07 | -$4.95M 10-Q · filed 2023-11-07 | -$5.01M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$5.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$3.39M 10-Q · filed 2023-08-07 | -$3.44M derived: sum of 3 quarters · filed 2024-02-27 | -$3.75M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $2.10M 10-Q · filed 2023-05-09 | $2.05M derived: sum of 2 quarters · filed 2024-02-27 | $1.74M derived: sum of 3 quarters · filed 2024-02-27 | |
| 2021-12-31 | -$57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$367.00K derived: sum of 2 quarters · filed 2024-02-27 | $4.95M 10-K · filed 2024-02-27 | |
| 2021-09-30 | -$310.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $5.01M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $5.32M 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |